Chris Boerner, Bristol Myers Squibb CEO (Tierney L. Cross/Bloomberg via Getty Images) December 3, 2025 07:41 AM EST Updated 10:06 AM R&D Up­dat­ed: Bris­tol My­ers push­es back Coben­fy read­out af­ter tri­al site 'ir­reg­u­lar­i­ties' Max Gelman Senior Editor Bris­tol My­ers Squibb’s hot­ly an­tic­i­pat­ed Coben­fy read­out in Alzheimer’s-as­so­ci­at­ed psy­chosis will have to wait. Be­cause of “ir­reg­u­lar­i­ties” at a “small num­ber” of tri­al sites, the … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER